In the current study, tumor stabilization occurred in some gastric cancer patients with an ontuxizumab treatment duration of ≥2 months, suggesting that endosialin inhibition could be a new therapeutic strategy for gastric cancer by targeting endosialin expression in CAFs. This evidence concerns the gene CD248 and gastric cancer.